Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Fadi Issa has received a gentleMACST Octo Dissociator from global biotechnology company Miltenyi Biotec following a competition draw.

© NDS
Dr Fadi Issa receiving the prize from Clare Marchant, Senior Account Manager at Miltenyi Biotec

The new tissue dissociator will help Dr Issa perform important experiments using standardised and reliable methods. This is particularly vital in the analysis of samples from clinical studies. The tissue dissociator breaks up lumps of tissue into either a cell suspension for cellular assays or a homogenate for the isolation of molecules, such as RNA or protein.

 

Making our experiments more efficient, reliable and standardised will really help advance our goals. - Dr Fadi Issa

Dr Issa, who is a clinician scientist in the Transplantation Research Immunology Group (TRIG) at the Nuffield Department of Surgical Sciences, will use the equipment to dissociate mouse heart, spleen and skin as well as human skin, intestine and umbilical cord. Breaking the tissue up into cells will enable him to isolate specific cell groups in order to analyse or culture the cells.

He said: 'I am very grateful to Miltenyi for providing us with this critical piece of equipment. Making our experiments more efficient, reliable and standardised will really help advance our goals. We have been working with Miltenyi for a number of years in both basic, translational and clinical studies and look forward to continuing this valuable relationship.'

Miltenyi Biotec donated the equipment as part of an international prize draw, in which professional graffiti and concept artist Lars Kesseler designed and hand-crafted a special edition of the prize. He had previously designed a different instrument - the autoMACS Pro Separator - to help celebrate the company's 25th anniversary.

Miltenyi Biotec is headquartered near Cologne in Bergisch Gladbach, Germany, and has offices across the globe. The company is a provider of products and services that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications.

Similar stories

New Cochrane evidence explores treatment options for chronic ear disease

Publication Research

A new Evidently Cochrane blog post for World Hearing Day summarises seven recent reviews on medical treatments for infection and inflammation of the middle ear.

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Applications for Oxford-Wolfson-Marriott-Patel Scholarship now open

Awards and appointments Department Research

The Nuffield Department of Surgical Sciences (NDS) are pleased to confirm that one scholarship will be available for Home (UK) and Republic of Ireland (ROI) candidates for the DPhil in Surgical Sciences, starting in Michaelmas Term 2021.

Oxford University breakthrough on global COVID-19 vaccine

Coronavirus COVID-19 Research

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.